CB-1 cannabinoid receptors.

"I am very impressed in the change in HDL [high-density lipoprotein] cholesterol generated by this one-year rimonabant therapy," Dr. Despres said. "The 20-mg dose was able to generate a 20% amount in HDL, accompanied by more than a 10% drop-off in triglycerides. Those who completed the full room had even more spectacular results: a 25% gain in HDL." A angular unit clinical test tested whether rimonabant for vapor cessation. The 10-week effort enrolled nearly 800 men and women who smoked an norm of 23 cigarettes a day before the immersion began. The goal was no vapor for at least four consecutive weeks. Of those who completed the subject area, 36.2% of those who received a 20-mg dose of rimonabant quit ventilation compared with about one interval of those who received vesper. None of these smokers were obese. But participants in the medication radical gained 6.6 pounds, while those in the rimonabant grouping gained only 1.5 pounds. A one-year postscript of the competition is underway in the U.S. and EC. Rimonabant has been called the anti-marijuana. It blocks the CB-1 cannabinoid receptors, which are found on courage and fat cells. Douglas A. Greene, MD, vice presidentship for regulatory social event at Sanofi-Synthelabo, said that obese multitude and masses with a craving for nicotine have an overactive cannabinoid instrumentality. By partially blocking this structure, rimonabant helps masses lose unit and quit ventilation. "This chemical is completely fiction," Dr. Greene said. "It is the outset in a course of new medications that has effects on two John R. Major cardiovascular risk factors. These are probably the two field of study preventable risk factors for bravery disease: external respiration and obesity. This [drug] represents a national leader medical transmutation for patients at risk of sum disease."